A.forall Announces ANDA Approval for Sodium Bicarbonate for Injection, USP

WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--A.forall announced through its U.S. subsidiary, Milla Pharmaceuticals Inc., that it has received Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (FDA) for 8.4% Sodium Bicarbonate Injection, USP 50 mEq/ 50 mL vials for intravenous use. Sodium Bicarbonate for Injection, USP is indicated as an alkalinizing agent to correct severe metabolic acidosis. The product has intermittently appeared on the FDA Drug shortages l

WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--A.forall announced through its U.S. subsidiary, Milla Pharmaceuticals Inc., that it has received Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (FDA) for 8.4% Sodium Bicarbonate Injection, USP 50 mEq/ 50 mL vials for intravenous use. Sodium Bicarbonate for Injection, USP is indicated as an alkalinizing agent to correct severe metabolic acidosis. The product has intermittently appeared on the FDA Drug shortages l